| Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview S Mondal, N Adhikari, S Banerjee, SA Amin, T Jha European journal of medicinal chemistry 194, 112260, 2020 | 386 | 2020 |
| HDAC6 as privileged target in drug discovery: A perspective S Pulya, SA Amin, N Adhikari, S Biswas, T Jha, B Ghosh Pharmacological research 163, 105274, 2021 | 144 | 2021 |
| Design of aminopeptidase N inhibitors as anti-cancer agents SA Amin, N Adhikari, T Jha Journal of Medicinal Chemistry 61 (15), 6468-6490, 2018 | 102 | 2018 |
| Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review R Sarkar, S Banerjee, SA Amin, N Adhikari, T Jha European journal of medicinal chemistry 192, 112171, 2020 | 90 | 2020 |
| Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview S Banerjee, N Adhikari, SA Amin, T Jha European Journal of Medicinal Chemistry 164, 214-240, 2019 | 90 | 2019 |
| Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview N Adhikari, A Mukherjee, A Saha, T Jha European Journal of Medicinal Chemistry 129, 72-109, 2017 | 68 | 2017 |
| Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study N Adhikari, SA Amin, A Saha, T Jha European Journal of Medicinal Chemistry 137, 365-438, 2017 | 67 | 2017 |
| Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? SA Amin, N Adhikari, T Jha Pharmacological Research 122, 8-19, 2017 | 65 | 2017 |
| HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches N Adhikari, SA Amin, P Trivedi, T Jha, B Ghosh European journal of medicinal chemistry 157, 1127-1142, 2018 | 58 | 2018 |
| Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling … SA Amin, S Bhargava, N Adhikari, S Gayen, T Jha Journal of Biomolecular Structure and Dynamics 36 (3), 590-608, 2018 | 58 | 2018 |
| Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead … N Adhikari, AK Halder, S Mallick, A Saha, KD Saha, T Jha Bioorganic & Medicinal Chemistry 24 (18), 4291-4309, 2016 | 55 | 2016 |
| Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects P Trivedi, N Adhikari, SA Amin, T Jha, B Ghosh European Journal of Pharmaceutical Sciences 124, 165-181, 2018 | 50 | 2018 |
| Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery TK Patel, N Adhikari, SA Amin, S Biswas, T Jha, B Ghosh New Journal of Chemistry 45 (12), 5291-5321, 2021 | 47 | 2021 |
| First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington’s disease: a proposal to chemists! SA Amin, N Adhikari, T Jha, S Gayen Bioorganic & Medicinal Chemistry Letters 26 (23), 5712-5718, 2016 | 46 | 2016 |
| First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors SA Amin, N Adhikari, S Gayen, T Jha Journal of Molecular Structure 1143, 49-64, 2017 | 42 | 2017 |
| Structure-activity relationships of HDAC8 inhibitors: non-hydroxamates as anticancer agents SA Amin, N Adhikari, T Jha Pharmacological Research 131, 128-142, 2018 | 41 | 2018 |
| Structure–activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery SA Amin, N Adhikari, T Jha Future Medicinal Chemistry 9 (18), 2211-2237, 2017 | 40 | 2017 |
| Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy N Adhikari, T Jha, B Ghosh Journal of Medicinal Chemistry 64 (13), 8827-8869, 2021 | 39 | 2021 |
| Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents C Mondal, AK Halder, N Adhikari, A Saha, KD Saha, S Gayen, T Jha European Journal of Medicinal Chemistry 90, 860-875, 2015 | 37 | 2015 |
| Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides SA Amin, N Adhikari, S Kotagiri, T Jha, B Ghosh European Journal of Medicinal Chemistry 166, 369-380, 2019 | 35 | 2019 |
Dr. Sk Abdul AminUniversità degli Studi di Salerno, SA, Italy在 studenti.unisa.it 的电子邮件经过验证
